Technology and regulation updates.

Four practical changes for pharmaceutical and life-sciences companies.

18 to 24 August 2026

4 reviewed updates

Technology Priority update

OpenAI's new safety check could protect private research and health data

OpenAI announced a way to spot harmful use across several requests without letting staff read the customer's questions or answers. This may help companies keep private research or health data under their control.

OpenAI offers Zero Data Retention to some customers. It reads a question, returns an answer, then keeps no copy. But current safety checks look at one request at a time. A person could split a harmful plan across several requests, so each may look safe alone.

Private Safety Processing checks related requests together. If it finds a pattern, it sends OpenAI an alert that names the risk. OpenAI says staff still cannot see the text. It is testing with early customers and plans to start a rollout and publish a paper in September. It has not shared test results or an outside audit. OpenAI source

Our thoughts.

Companies need strict rules for private research and health data. The tool may protect that data while OpenAI checks for abuse. Companies can list the uses they would review if the design meets their data rules. When the paper appears, teams should check what data leaves the company, what an alert contains, and how to fix a wrong alert. Those checks should decide whether a sensitive use can enter a controlled pilot.

Related analysisFrom AI use case to validated GxP tool
Technology

OpenAI's temporary price cut could lower the cost of large research and document projects

OpenAI cut the price of GPT-5.6 Sol on Amazon Bedrock. Bedrock is an AWS service that lets companies run models through their own software. The new rate is $4 per million input tokens, the text sent to the model, and $20 per million output tokens, the text it creates.

For teams that process many long documents or run research in several steps, model fees grow with every token. A small test may cost little. A service used thousands of times can become expensive.

AWS says the new input price is 20 percent lower and the output price is 33.3 percent lower. The offer starts now and lasts at least through November 21, 2026. AWS does not say what happens after that date. The announcement also gives no pharmaceutical case and does not prove that this model meets a company's quality, security, or data rules. AWS pricing notice

Our thoughts.

The price cut matters only for projects that already work and use the model at high volume. Companies can compare their current monthly token use with the new rate now. Before November 21, teams should check the real savings, output quality, and likely price after the offer. That review should decide whether to expand the project, keep its current size, or move it to another model.

Technology

AWS now lets pharmaceutical teams keep web research within approved sources

AWS added website and date filters to Web Search in Bedrock AgentCore. The tool lets an AI agent search the web before it writes an answer. An AI agent is software that can plan and finish several steps.

Before this change, a company could set one broad list of sources. A single search could not add its own list of sites and dates. One drug safety team may need FDA, NIH, and ClinicalTrials.gov, while another team needs a different list.

Now each search can name allowed or blocked sites and a date range. Company rules still win, so a search cannot open a blocked site. AWS says the feature is available now in Virginia, Ireland, and Tokyo. Its pharmaceutical example limits results to FDA, NIH, and ClinicalTrials.gov. The company has not shared an outside test that shows how often the filters miss useful sources. AWS product notice AWS technical guide

Our thoughts.

Teams can enforce source rules before search results reach the model. Companies can test the tool on one low-risk task now and compare it with the current process. During that test, teams should measure missed sources, wrong dates, citation quality, and review time. That evidence should decide whether controlled web search is ready for wider use or needs a tighter source list.

Related use caseDetect adverse event signals in literature
Technology

Pudu's driverless forklift could reduce manual pallet moves without changing warehouse floors

Pudu Robotics launched the MP2000, a driverless forklift that can carry up to 2,000 kg. Pudu says it can map a site and move pallets without fixed signs, QR codes, or floor changes. This could make it easier to test robot pallet moves in an existing warehouse.

Many warehouse robots need fixed signs, planned routes, and setup projects. Drug plants add a need. If a pallet move supports controlled production, the site must know where each load went and if the move followed the approved process.

The MP2000 uses sensors and cameras to find objects, find load points, and adjust when a pallet is not straight. Pudu says several robots can share work. The Robot Report confirmed the launch but did not test the robot at a drug plant. Neither source gives a price. Pudu announcement Independent coverage

Our thoughts.

Fewer site changes could lower the cost of automating repeat routes. A company can map one route between a warehouse and production area now. It can then compare the robot with its safety, tracking, and system needs. A live test should check stops, bad pallet positions, route changes, records, and how people take control. Those results should decide if the route can enter a controlled pilot and what proof a site needs before regulated use.